A 52-year-old man with a history of malignant hyperthermia (MH) susceptibility is scheduled for elective inguinal hernia repair under general anesthesia. The anesthesiologist plans to use a total intravenous anesthesia (TIVA) technique with propofol and remifentanil, avoiding all volatile anesthetics. However, the operating room has just received a new delivery of inhalational agents. The surgeon asks why volatile anesthetics cannot be used in this patient. Which of the following inhalational agents has the LOWEST risk of triggering malignant hyperthermia and could theoretically be used as an alternative if TIVA were contraindicated?

Explanation

## Malignant Hyperthermia and Volatile Anesthetics **Key Point:** All halogenated volatile anesthetics (sevoflurane, desflurane, isoflurane) are known triggers of malignant hyperthermia in susceptible individuals. Nitrous oxide, a non-halogenated inert gas, does NOT trigger MH and is considered safe in MH-susceptible patients. ### Classification of Inhalational Agents by MH Risk | Agent | Halogenated | MH Trigger | Safe in MH | |-------|-------------|-----------|------------| | Sevoflurane | Yes | Yes | No | | Desflurane | Yes | Yes | No | | Isoflurane | Yes | Yes | No | | Nitrous oxide | No | No | **Yes** | **High-Yield:** Nitrous oxide is the ONLY volatile agent that does not trigger MH. It is non-halogenated and inert, making it safe for use in MH-susceptible patients if volatile anesthesia is absolutely necessary (though TIVA remains the gold standard). ### Why Halogenated Agents Trigger MH Halogenated volatile anesthetics bind to the ryanodine receptor (RYR1) on the sarcoplasmic reticulum of skeletal muscle, causing uncontrolled calcium release in genetically susceptible individuals. This leads to: 1. Sustained muscle contraction and rigidity 2. Hypermetabolism and heat production 3. Rhabdomyolysis and myoglobinuria 4. Acidosis and hyperkalemia 5. Potential cardiac arrhythmias and death **Clinical Pearl:** Even though nitrous oxide is technically safe in MH patients, the standard of care remains TIVA (propofol + opioid) combined with non-depolarizing neuromuscular blockers and local/regional anesthesia when possible. **Warning:** Do not confuse "safe in MH" with "preferred in MH." Nitrous oxide is safe but is rarely used as a sole agent due to its weak analgesic and amnestic properties and the risk of diffusion hypoxia. TIVA is the gold standard. ### Mechanism of MH Susceptibility MH is an autosomal dominant pharmacogenetic disorder caused by mutations in: - RYR1 gene (ryanodine receptor) — ~70% of cases - CACNA1S gene (L-type calcium channel) — ~20% of cases These mutations predispose the sarcoplasmic reticulum to uncontrolled calcium efflux when exposed to triggering agents.